Cargando…
Adenovirus vector-based vaccine for infectious diseases
Replication-incompetent adenovirus (Ad) vectors have been widely used as gene delivery vehicles in both gene therapy studies and basic studies for gene function analysis due to their highly advantageous properties, which include high transduction efficiencies, relatively large capacities for transge...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585960/ https://www.ncbi.nlm.nih.gov/pubmed/34974335 http://dx.doi.org/10.1016/j.dmpk.2021.100432 |
_version_ | 1784597796543791104 |
---|---|
author | Sakurai, Fuminori Tachibana, Masashi Mizuguchi, Hiroyuki |
author_facet | Sakurai, Fuminori Tachibana, Masashi Mizuguchi, Hiroyuki |
author_sort | Sakurai, Fuminori |
collection | PubMed |
description | Replication-incompetent adenovirus (Ad) vectors have been widely used as gene delivery vehicles in both gene therapy studies and basic studies for gene function analysis due to their highly advantageous properties, which include high transduction efficiencies, relatively large capacities for transgenes, and high titer production. In addition, Ad vectors induce moderate levels of innate immunity and have relatively high thermostability, making them very attractive as potential vaccine vectors. Accordingly, it is anticipated that Ad vectors will be used in vaccines for the prevention of infectious diseases, including Ebola virus disease and acquired immune deficiency syndrome (AIDS). Much attention is currently focused on the potential use of an Ad vector vaccine for coronavirus disease 2019 (COVID-19). In this review, we describe the basic properties of an Ad vector, Ad vector-induced innate immunity and immune responses to Ad vector-produced transgene products. Development of novel Ad vectors which can overcome the drawbacks of conventional Ad vector vaccines and clinical application of Ad vector vaccines to several infectious diseases are also discussed. |
format | Online Article Text |
id | pubmed-8585960 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85859602021-11-12 Adenovirus vector-based vaccine for infectious diseases Sakurai, Fuminori Tachibana, Masashi Mizuguchi, Hiroyuki Drug Metab Pharmacokinet Review Article Replication-incompetent adenovirus (Ad) vectors have been widely used as gene delivery vehicles in both gene therapy studies and basic studies for gene function analysis due to their highly advantageous properties, which include high transduction efficiencies, relatively large capacities for transgenes, and high titer production. In addition, Ad vectors induce moderate levels of innate immunity and have relatively high thermostability, making them very attractive as potential vaccine vectors. Accordingly, it is anticipated that Ad vectors will be used in vaccines for the prevention of infectious diseases, including Ebola virus disease and acquired immune deficiency syndrome (AIDS). Much attention is currently focused on the potential use of an Ad vector vaccine for coronavirus disease 2019 (COVID-19). In this review, we describe the basic properties of an Ad vector, Ad vector-induced innate immunity and immune responses to Ad vector-produced transgene products. Development of novel Ad vectors which can overcome the drawbacks of conventional Ad vector vaccines and clinical application of Ad vector vaccines to several infectious diseases are also discussed. The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. 2022-02 2021-11-12 /pmc/articles/PMC8585960/ /pubmed/34974335 http://dx.doi.org/10.1016/j.dmpk.2021.100432 Text en © 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Sakurai, Fuminori Tachibana, Masashi Mizuguchi, Hiroyuki Adenovirus vector-based vaccine for infectious diseases |
title | Adenovirus vector-based vaccine for infectious diseases |
title_full | Adenovirus vector-based vaccine for infectious diseases |
title_fullStr | Adenovirus vector-based vaccine for infectious diseases |
title_full_unstemmed | Adenovirus vector-based vaccine for infectious diseases |
title_short | Adenovirus vector-based vaccine for infectious diseases |
title_sort | adenovirus vector-based vaccine for infectious diseases |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585960/ https://www.ncbi.nlm.nih.gov/pubmed/34974335 http://dx.doi.org/10.1016/j.dmpk.2021.100432 |
work_keys_str_mv | AT sakuraifuminori adenovirusvectorbasedvaccineforinfectiousdiseases AT tachibanamasashi adenovirusvectorbasedvaccineforinfectiousdiseases AT mizuguchihiroyuki adenovirusvectorbasedvaccineforinfectiousdiseases |